FDA To Examine Safety Impact Of Color In Drug Labeling, Packaging
This article was originally published in The Pink Sheet Daily
Executive Summary
A March 7 public hearing will help the agency determine the benefits and potential drawbacks to patient safety. FDA seeks input on whether there are specific classes of drugs where use of color has demonstrated value or posed a hindrance to public safety.